Research shows that puberty blockers, when prescribed appropriately, have a well-established safety profile in medical practice. These medications were originally developed and extensively tested for treating precocious puberty, where children as young as four or five begin puberty inappropriately early. In this context, they have been routinely prescribed for decades with documented safety outcomes.
Evidence indicates that puberty blockers work by temporarily pausing the physical changes of puberty, creating what medical professionals describe as a reversible pause. When the medication is stopped, puberty typically resumes its natural course. For transgender young people, these medications are actually prescribed at ages later than their original medical application, as they prevent the distressing experience of going through puberty that doesn't align with their gender identity.
Guidelines recommend that puberty blockers be prescribed as part of comprehensive care involving mental health support and ongoing medical monitoring. The medications allow young people time to explore their gender identity without the pressure of irreversible physical changes, providing space for careful consideration of future treatment options.
Like all medications, puberty blockers do carry potential side effects that require monitoring, including impacts on bone density and growth. Medical professionals emphasise the importance of regular check-ups and individualised assessment to ensure the benefits outweigh any risks for each young person's specific circumstances.